Thermo Fisher Scientific Adds Aseptic Capacity
The Pharma Services business of Thermo Fisher Scientific will invest $150 Million at three facilities.
Thermo Fisher Scientific Inc. will invest $150 million at three Pharma Services business sites in Monza and Ferentino, Italy, and Greenville, NC to add capacity for sterile liquid and lyophilized product development and commercial manufacturing.
Each site will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next 24 months, the company reported in a March 18, 2019 press statement announcing the investment.
"These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise," said Michel Lagarde, president of pharma services for Thermo Fisher Scientific. "We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them."
Source: Thermo Fisher Scientific
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
